XOMA Royalty Corporation

XOMA Royalty Corporation

XOMANYSE / NASDAQHealthcareSmall cap

$40.17$0.00 (0.0%)

Last close · Data as of Jul 21, 2026

Market cap
$531.7M
P/E
16.8x
EV / EBITDA
12.1x
Revenue
$11.7M
Net margin
272.0%
ROCE
4.8%

Hidden because the last close is more than three trading days older than the latest prices of its class.

XOMA Royalty Corporation price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 21 Jul 2026 close.

1M
Stale
3M
Stale
6M
Stale
1Y
Stale
5Y
Stale
  • Hidden because the last close is more than three trading days older than the latest prices of its class.

52-week range

Day change $0.00 (0.0%) from $40 to $40 · Last close Jul 21, 2026

Best weekday to invest, historically

The same weekly amount in XOMA, bought on each weekday since 2021.

News & filings

What XOMA Royalty filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthReturn on equity of 37.8%.

Concerns (1)

  • Operating cash flow was 0.09 times net profit in fiscal 2025.
  • Prices are as of 21 Jul 2026; price-based points are paused until newer prices arrive.

Prices to the 21 Jul 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates.

Read moreShow less

XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to sponsors or developers; and acquires milestone and royalty revenue streams on late-stage clinical assets and commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

Sector
Healthcare
Shares outstanding
20.7M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$531.7M
P/E
16.8x
P/B
6.3x
EV / EBITDA
12.1x
EV / Sales
49.8x
P/S
45.6x
52-week high
$45.00
52-week low
$22.89

Profitability

Operating margin
97.6%
Net margin
272.0%
EBITDA margin
410.1%
ROE
37.8%
ROCE
4.8%
ROIC
33.7%
ROA
11.6%
Asset turnover
0.04

Growth

Revenue
$11.7M
Revenue growth, 1Y
14.1%
Revenue CAGR, 3Y
24.6%
Net profit growth, 1Y
-329.4%
Free cash flow
-$17.9M

Solvency

Current ratio
3.37
Debt / Equity
1.57
Debt / Assets
0.48
CFO / Net profit
0.09
Cash / Market cap
15.6%

Where the revenue went

Of every $100 of FY2025 revenue, $272 was left as net income.

XOMA Royalty Corporation income statement flow, FY2025
XOMA Royalty Corporation income statement flow, FY2025: flows
FromToAmount
RevenueGross profit$11.7M
Gross profitOperating expenses$280.0k
Gross profitOperating income$11.4M
Operating incomePretax income$11.4M
Interest and other incomePretax income$20.4M
Pretax incomeTax and other$110.0k
Pretax incomeNet income$31.7M

Revenue and net profit

Revenue grew 14.1% in FY2025; net profit is the dashed line.

XOMA Royalty Corporation revenue and net profit by fiscal year
XOMA Royalty Corporation revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$6.0M-$17.1M
FY2023$4.8M-$40.8M
FY2024$10.2M-$13.8M
FY2025$11.7M$31.7M

Cash flows

FY2025: $2.9M from operations, -$17.9M free after investment (dashed).

XOMA Royalty Corporation operating and free cash flow by fiscal year
XOMA Royalty Corporation operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$12.9M-$28.1M
FY2023-$18.2M-$18.2M
FY2024-$13.7M-$13.8M
FY2025$2.9M-$17.9M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$11.7M+14.1%1Y
EBITDA
$47.8M
Net profit
$31.7M
Cash from operations
$2.9M
Free cash flow
-$17.9M
Revenue CAGR, 3Y
24.6%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$11.7M$47.8M$31.7M-$17.9M37.8%+14.1%-329.4%

Monthly returns

Month-by-month returns of XOMA across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$272.7M
Liabilities$188.8M
Equity$83.9M
Paid-in capital$1.3B
Retained earnings-$1.2B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; XOMA highlighted.

P/E against peers

XOMA trades at 16.8x earnings against a peer median of -6.2x.

  1. XOMA Royalty Corporation (this company)16.8x

Not shown (no positive earnings and no EV / Sales): Tectonic Therapeutic, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
XOMA Royalty CorporationXOMAthis company$531.7M16.8x6.3x37.8%12.1x
Cerus CorporationCERS$559.0M—8.7x-24.3%—
NeuroPace, Inc.NPCE$556.4M-25.9x29.2x-112.8%-50.2x
Fulgent Genetics, Inc.FLGT$553.8M-9.2x0.5x-5.4%-11.2x
Tectonic Therapeutic, Inc.TECX$549.7M-7.4x2.2x-29.5%-4.2x
Strata Critical Medical, Inc.SRTA$541.7M13.1x1.9x14.8%-36.3x
4D Molecular Therapeutics, Inc.FDMT$523.3M-3.7x1.0x-27.7%-3.2x
Aquestive Therapeutics, Inc.AQST$519.4M-6.2x-15.4x248.9%-6.7x
Pacific Biosciences of California, Inc.PACB$506.3M-0.9x94.6x-10214.5%-7.5x
Peer median—-6.2x2.1x-26.0%-7.5x

Year-to-date ROI

XOMA since 1 January, against earlier years.

Historical volatility

XOMA's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

XOMA Royalty Corporation operating margin by fiscal year
XOMA Royalty Corporation operating margin by fiscal year
DateOperating margin
FY2022-288.7%
FY2023-492.9%
FY2024-391.2%
FY202597.6%
LineFY2025
Operating expensesOperating Expense$280.0k
Research and developmentResearch And Development$1.7M
Other operating expensesOther Operating Expenses-$40.5M
Depreciation and amortisationDepreciation And Amortization In Income Statement$3.0M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$3.0M
Amortization$3.0M
Amortisation of intangiblesAmortization Of Intangibles Income Statement$3.0M
Provision for doubtful accountsProvision For Doubtful Accounts$0.00
Total expensesTotal Expenses$280.0k
Pretax incomePretax Income$31.8M

Learn while you research

Academy chapters picked for XOMA Royalty Corporation and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Leverage RatiosDebt/Equity of 1.57 is elevated, understand what that means for solvency.6 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →